Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.

The FDA made public a voluntary recall of sterile injectables made by Coastal Meds of Mississippi, after visible particles were found in some vials.

It’s been a strange road for BMS' Opdivo-Yervoy combo in first-line kidney cancer, but the New Jersey drugmaker finally has a go-ahead.

Merck's Gardasil 9 has been on an upward trajectory, but high global demand for the HPV shot has created a shortage for U.K. private clinics.

At €350 million, Sanofi's new Canadian vaccine plant will be one of the largest investments ever by the company in a single facility.

The FDA hit New Jersey-based CMO Tris Pharma with a warning letter, citing significant violations.

Spurred by U.S. tax breaks, Amgen will build a $165 million next-generation biologics plant in West Greenwich, Rhode Island.